-+ 0.00%
-+ 0.00%
-+ 0.00%

AIM ImmunoTech CEO and President Thomas K Equels reports $5,130 common share acquisition

PUBT·11/17/2026 15:01:55
Listen to the news
AIM ImmunoTech CEO and President Thomas K Equels reports $5,130 common share acquisition
  • AIM ImmunoTech CEO, President and director Thomas K. Equels purchased 38,000 shares of Common Stock at $0.135 each.
  • The purchase brought his direct beneficial ownership to 366,095 shares.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-052742), on November 17, 2026, and is solely responsible for the information contained therein.